4924 , a NEDD 8-activating enzyme inhibitor , is active in diffuse large B-cell lymphoma models : rationale for treatment of NF-B – dependent lymphoma *
暂无分享,去创建一个
L. Staudt | U. Narayanan | L. Dang | Peter G. Smith | M. Rolfe | T. Soucy | M. Milhollen | A. Berger | J. Garnsey | Michael P. Thomas | T. Traore | Jie Yu | Julie Zhang | L. Dick | J. Bolen | S. Langston | M. Manfredi | Erik Koenig | Jennifer Adams-Duffy
[1] D. Baltimore,et al. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. , 1990, Nature.
[2] D B Young,et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. , 1997, Science.
[3] B. Dörken,et al. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells , 1999, Oncogene.
[4] R. Hay,et al. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. , 1999, Oncogene.
[5] E. Yeh,et al. Identification of the Activating and Conjugating Enzymes of the NEDD8 Conjugation Pathway* , 1999, The Journal of Biological Chemistry.
[6] V. Chau,et al. Nedd8 Modification of Cul-1 Activates SCFβTrCP-Dependent Ubiquitination of IκBα , 2000, Molecular and Cellular Biology.
[7] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[8] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[9] S. Alkan,et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. , 2001, British journal of haematology.
[10] Michael Karin,et al. NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.
[11] A. Fong,et al. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100. , 2002, The Journal of biological chemistry.
[12] A. Ciechanover,et al. The NEDD8 pathway is essential for SCF(beta -TrCP)-mediated ubiquitination and processing of the NF-kappa B precursor p105. , 2002, The Journal of biological chemistry.
[13] R. Siebert,et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. , 2003, Blood.
[14] Anindya Dutta,et al. A p53-dependent checkpoint pathway prevents rereplication. , 2003, Molecular cell.
[15] J. Bartek,et al. Loss of Geminin induces rereplication in the presence of functional p53 , 2004, The Journal of cell biology.
[16] N. Perkins,et al. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. , 2004, Molecular cell.
[17] M. Toi,et al. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.
[18] T. Golub,et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. , 2005, Blood.
[19] L. Staudt,et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] Raymond J. Deshaies,et al. Function and regulation of cullin–RING ubiquitin ligases , 2005, Nature Reviews Molecular Cell Biology.
[21] Liming Yang,et al. A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.
[22] M. Fujita. Cdt1 revisited: complex and tight regulation during the cell cycle and consequences of deregulation in mammalian cells , 2006, Cell Division.
[23] J. Ruland,et al. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. , 2007, Blood.
[24] Jan Delabie,et al. Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.
[25] Riccardo Dalla-Favera,et al. Germinal centres: role in B-cell physiology and malignancy , 2008, Nature Reviews Immunology.
[26] L. Staudt,et al. Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screen , 2008, Proceedings of the National Academy of Sciences.
[27] R. Dalla‐Favera,et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.
[28] S. Ogawa,et al. Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.
[29] Amanda Doucette,et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.
[30] J. Ruland,et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells , 2009, The Journal of experimental medicine.
[31] L. Staudt,et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. , 2009, Blood.
[32] Peter G. Smith,et al. Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer , 2009, Clinical Cancer Research.
[33] Jan Delabie,et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.
[34] Ping Li,et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. , 2010, Molecular cell.